期刊
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
卷 41, 期 1, 页码 -出版社
BMC
DOI: 10.1186/s13046-022-02449-4
关键词
RPRD1B; Lymph node metastasis; Fatty acid metabolism; c-Jun/c-Fos/SREBP1 axis; NEAT1; hnRNPA2B1; TRIM25
类别
资金
- National Key R&D Program of China [2017YFC1309000]
- Hong Kong Research Grant Council (RGC) [17143716]
- Collaborative Research Funds [C703814G]
- National Natural Science Foundation of China [82203852, 81472605, 81472250, 81772554]
This study identified a key molecular mechanism that influences lymph node metastasis. RPRD1B was found to promote lymph node metastasis by regulating the c-Jun/c-Fos/SREBP1 axis, and NEAT1 enhanced the activity of this axis through a positive feedback loop. These findings provide a potential therapeutic target for the treatment of gastric cancer.
Background: Lymph node metastasis is one of most common determinants of the stage and prognosis of gastric cancer (GC). However, the key molecular events and mechanisms mediating lymph node metastasis remain elusive. Methods: RNA sequencing was used to identify driver genes responsible for lymph node metastasis in four cases of gastric primary tumors, metastatic lesions of lymph nodes and matched normal gastric epithelial tissue. qRT-PCR and IHC were applied to examine RPRD1B expression. Metastatic functions were evaluated in vitro and in vivo. RNAseq was used to identify target genes. ChIP, EMSA and dual luciferase reporter assays were conducted to identify the binding sites of target genes. Co-IP, RIP, MeRIP, RNA-FISH and ubiquitin assays were applied to explore the underlying mechanisms. Results: The top 8 target genes (RPRD1 B, MAP4K4, MCM2,TOPBP1, FRMD8, KBTBD2, ADAM10 and CXCR4) that were significantly upregulated in metastatic lymph nodes of individuals with GC were screened. The transcriptional cofactor RPRD1B (regulation of nuclear pre-mRNA domain containing 1B) was selected for further characterization. The clinical analysis showed that RPRD1B was significantly overexpressed in metastatic lymph nodes and associated with poor outcomes in patients with GC. The Mettl3-induced m(6)A modification was involved in the upregulation of RPRD1B. Functionally, RPRD1B promoted lymph node metastasis capabilities in vitro and in vivo. Mechanistic studies indicated that RPRD1B increased fatty acid uptake and synthesis by transcriptionally upregulating c-Jun/c-Fos and activating the c-Jun/c-Fos/SREBP1 axis. In addition, NEAT1 was upregulated significantly by c-Jun/c-Fos in RPRD1 Boverexpressing cells. NEAT1, in turn, increased the stability of the RPRD1B mRNA by recruiting the m(6)Areader protein hnRNPA2B1 and reduced the degradation of the RPRD1B protein by inhibiting TRIM25-mediated ubiquitination. Notably, this functional circuitry was disrupted by an inhibitor of c-Jun/c-Fos/AP1 proteins (SR11302) and small interfering RNAs targeting NEAT1, leading to a preferential impairment of lymph node metastasis. Conclusions: Based on these findings, RPRD1B facilitated FA metabolism and assisted primary tumor implantation in lymph nodes via the c-Jun/c-Fos/SREBP1 axis, which was enhanced by a NEAT1-mediated positive feedback loop, serving as a potential therapeutic target for GC treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据